<DOC>
	<DOCNO>NCT00422552</DOCNO>
	<brief_summary>The purpose study assess change inspiratory capacity lung function patient chronic obstructive pulmonary disease treat indacaterol compare placebo formoterol .</brief_summary>
	<brief_title>Effect Indacaterol Inspiratory Capacity Lung Function Patients With COPD Versus Placebo Formoterol</brief_title>
	<detailed_description />
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Male postmenopausal female adult age 4080 year inclusive . Patients clinical diagnosis COPD accord Global Initiative Chronic Lung Disease ( GOLD ) Guidelines ( 2005 ) Smoking history least 10 pack year ( either smoker exsmokers ) . Able perform reproducible spirometry maneuver . Able communicate well investigator , understand comply requirement study . Understand sign write informed consent . COPD exacerbation within 6 week prior dose Concomitant lung disease asthma , requirement long term oxygen treatment history lung reduction surgery . Medical condition would interfere performance spirometry may pose potential hazard perform spirometry . Any medical condition opinion Investigator may cause patient unsuitable completion study place patient potential risk study , e.g . uncontrolled hypertension , unstable ischemic heart disease . Participation clinical investigation within 4 week prior dose longer required local regulation , limitation participation base local regulation . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>inspiratory capacity , FEV1 , COPD</keyword>
</DOC>